AzTrials
AzTrials

ST-segment Elevation Myocardial Infarction (STEMI)NCT03768453

EARLY-MYO-CMR Registry

An observational study of ST-segment Elevation Myocardial Infarction (STEMI), run by RenJi Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this registry is to depict the myocardial tissue characteristics in STEMI patients by CMR and other cardiac imaging modalities and to assess the prognostic value of imaging-derived indices. Information will be collected prospectively in about 1000 STEMI patients in 10 sites. Read more about this study

Who is it for?
Ages 18 years and older
How many people
1,000 participants
Where
1 siteChina
Study dates
8 May 2012to 1 Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: STEMI patients undergo CMR examination are eligible for this registry.

Who may be able to join

  • STEMI patients who have had CMR imaging performed and have provided written consent.
  • Patents older than 18 years old with myocardial infarction diagnosed by:
  • typical ischemic symptom,
  • New ischaemic ECG changes;: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ;
  • elevated cardiac troponin value with at least one value above 99th percentile upper reference limit(UPL);
  • confirmed by coronary angiography (CAG) or imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology.
  • Patients who have had CMR imaging performed and have agreed to comply with the follow up requirements.

Who cannot join

  • Patient who is unable to comply with the follow-up schedule.
  • Patient who has any medical conditions that in the opinion of the investigators will not be appropriate to participate in the study.
  • Patient has a life expectancy of less than 6 months due to any condition.

Trial locations and contacts

1 site in 1 country.

Jun Pu contact

08602168383164

pujun310@hotmail.com

Heng Ge contact

08602168383164

dr.geheng@foxmail.com

China1 site, 1 recruiting

  • Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, 200127

    Jun Pu, Professor, 86-21-68383477, pujun310@hotmail.com

    Recruiting

Other trials in China

About this study

Official title: EARLY-MYO-CMR (EARLY Assessment of MYOcardial Tissue Characteristics by CMR in STEMI) Registry

The purpose of this registry is to depict the myocardial tissue characteristics in STEMI patients by CMR and other cardiac imaging modalities and to assess the prognostic value of imaging-derived indices. Information will be collected prospectively in about 1000 STEMI patients in 10 sites. Subjects will be followed for up to 5 years.

Read the detailed description

This is a prospective, multi-center, non-randomized, observational registry study of STEMI patients that undergo CMR examination. Information of other cardiac imagings and clinical outcomes are also prospectively collected in the database. This project will establish a prospective registry of 1000 STEMI patients in 10 sites with follow-ups of up to 5 years.

The aim of the project will be as following:

  1. To investigate myocardial tissue features and functional changes in STEMI patients.
  2. To identify CMR-derived indices that are associated with adverse clinical outcomes.
  3. To compare CMR with other alternative cardiac imaging modalities (i.e., echocardiography or SPECT) on prognostic prediction in STEMI patients.
  4. To compare myocardial tissue characteristics and functional changes in STEMI and NSTEMI patients (data derived from EARLY-MYO-CMR II Registry).
Medical subject headings
ST Elevation Myocardial Infarction

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Major adverse cardiac events

    MACE

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Dec 2018
  2. Study start8 May 2012
  3. Primary completion8 Jul 2020 (estimated)
  4. Study completion1 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03768453
Sponsor's protocol ID
EARLY-MYO-CMR
Status last verified
Jun 2019
First submitted
3 Dec 2018
Last updated
23 Jun 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Jiang YJ, Wei L, Hou XC, Zhao Q, Zhao CX, Dong JX, Ge H, Yang YN, Pu J. The FIBR-CMR score: a novel risk model integrating fibrinogen and cardiac magnetic resonance for major adverse events after STEMI. Radiol Med. 2026 Oct 22. doi: 10.1007/s11547-026-02285-y. Online ahead of print.

    PubMed 42911529

  • Chen Y, Jiang M, Xia C, Zhao H, Ke P, Chen S, Ge H, Li K, Wang X, Wang Y, Chai Y, Liu Q, Tao Z, Lyu Y, Wu Y, Shi A, Liu Y, Xin H, Zhong Y, Zhang W, Yan F, Quan W, Xu Y, Liu D, Sun Y, Li X, Tian Y, Wu L, Tu S, Ji H, Sheng B, Pu J. A novel deep learning system for STEMI prognostic prediction from multi-sequence cardiac magnetic resonance. Sci Bull (Beijing). 2025 Dec 30;70(24):4241-4252. doi: 10.1016/j.scib.2025.11.027. Epub 2025 Nov 17.

    PubMed 41314962

  • Dong JX, Wei L, Jin LX, He J, Zhao CX, Ding S, Kong LC, Yang F, An DA, Wu CW, Chen BH, Wang HW, Yang YN, Ge H, Pu J. MR Uniformity Ratio Estimates to Evaluate Ventricular Mechanical Dyssynchrony and Prognosis After ST-Segment Elevation Myocardial Infarction. J Magn Reson Imaging. 2024 May;59(5):1820-1831. doi: 10.1002/jmri.28998. Epub 2023 Oct 13.

    PubMed 37830268

  • Lai W, Chen-Xu Z, Jian-Xun D, Jie H, Ling-Cong K, Dong-Ao-Lei A, Bing-Hua C, Song D, Zheng L, Fan Y, Hu-Wen W, Jian-Rong X, Heng G, Jun P. Prognostic implications of left ventricular torsion measured by feature-tracking cardiac magnetic resonance in patients with ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging. 2023 May 31;24(6):785-795. doi: 10.1093/ehjci/jeac177.

    PubMed 36056877

  • Zhao Y, Lu X, Wan F, Gao L, Lin N, He J, Wei L, Dong J, Qin Z, Zhong F, Qiao Z, Wang W, Ge H, Ding S, Yang Y, Xiu J, Shan P, Yan F, Zhao S, Ji Y, Pu J. Disruption of Circadian Rhythms by Shift Work Exacerbates Reperfusion Injury in Myocardial Infarction. J Am Coll Cardiol. 2022 May 31;79(21):2097-2115. doi: 10.1016/j.jacc.2022.03.370.

    PubMed 35618347

  • Lai W, Jie H, Jian-Xun D, Ling-Cong K, Jun-Tong Z, Bo-Zhong S, Dong-Ao-Lei A, Bing-Hua C, Song D, Zheng L, Fan Y, Yi-Ning Y, Fu-Hua Y, Jian-Cheng X, Hu-Wen W, Jian-Rong X, Heng G, Jun P. Impact of Concomitant Impairments of the Left and Right Ventricular Myocardial Strain on the Prognoses of Patients With ST-Elevation Myocardial Infarction. Front Cardiovasc Med. 2021 May 31;8:659364. doi: 10.3389/fcvm.2021.659364. eCollection 2021.

    PubMed 34136542

Questions about this trial

What is this clinical trial studying?

An observational study of ST-segment Elevation Myocardial Infarction (STEMI), run by RenJi Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jun Pu (08602168383164, pujun310@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Major adverse cardiac events (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03768453, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2020; AzTrials last refreshed its copy on 3 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in